Atb Cap Markets Has Weak Forecast for Tilray FY2028 Earnings

Tilray Inc (NASDAQ:TLRY) – Analysts at Atb Cap Markets decreased their FY2028 earnings per share (EPS) estimates for Tilray in a report issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings of $0.01 per share for the year, down from their previous estimate of $0.06. The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share.

Separately, Roth Mkm decreased their target price on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research report on Friday, October 11th.

Tilray Stock Performance

Shares of NASDAQ TLRY opened at $1.16 on Wednesday. The business has a 50 day simple moving average of $1.45 and a 200 day simple moving average of $1.66. Tilray has a 52 week low of $1.15 and a 52 week high of $2.97. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.30 and a beta of 2.08. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.57 and a current ratio of 2.47.

Tilray (NASDAQ:TLRY) last released its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The firm had revenue of $200.00 million for the quarter, compared to analyst estimates of $218.70 million. During the same quarter in the prior year, the business earned ($0.10) EPS. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year.

Insider Activity at Tilray

In other Tilray news, CFO Carl A. Merton bought 26,000 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the purchase, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.87% of the stock is owned by company insiders.

Institutional Trading of Tilray

Several institutional investors have recently modified their holdings of TLRY. Synovus Financial Corp boosted its stake in Tilray by 176.7% in the 3rd quarter. Synovus Financial Corp now owns 36,092 shares of the company’s stock valued at $64,000 after buying an additional 23,046 shares in the last quarter. Barclays PLC raised its position in Tilray by 600.4% in the 3rd quarter. Barclays PLC now owns 204,144 shares of the company’s stock valued at $359,000 after purchasing an additional 174,997 shares during the last quarter. Toronto Dominion Bank boosted its stake in Tilray by 454.5% in the third quarter. Toronto Dominion Bank now owns 128,923 shares of the company’s stock worth $227,000 after purchasing an additional 105,671 shares in the last quarter. XTX Topco Ltd boosted its stake in Tilray by 1,079.7% in the third quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock worth $495,000 after purchasing an additional 257,641 shares in the last quarter. Finally, State Street Corp increased its position in Tilray by 4.7% in the 3rd quarter. State Street Corp now owns 1,961,338 shares of the company’s stock valued at $3,452,000 after acquiring an additional 88,079 shares in the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.